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Abstract: Kynurenic acid (KYNA) has well-established protective properties against
glutamatergic neurotransmission, which plays an essential role in the activation and
sensitization process during headache disorders. The goal of this study was to
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compare the effects of two KYNA analogs, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride (KA-1) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride (KA-2), in the orofacial formalin test of
trigeminal pain. Following pretreatment with KA-1 or KA-2, rats were injected with
subcutaneous formalin solution in the right whisker pad. Thereafter, the rubbing activity
and c-Fos immunoreactivity changes in the spinal trigeminal nucleus pars caudalis
(TNC) were investigated. To obtain pharmacokinetic data, KA-1, KA-2 and KYNA
concentrations were measured following KA-1 or KA-2 injection. Behavioral tests
demonstrated that KA-2 induced a larger amelioration of formalin-evoked alterations as
compared with KA-1 and the assessment of c-Fos immunoreactivity in the TNC yielded
similar results. Although KA-1 treatment resulted in approximately four times larger
area under the curve values in the serum relative to KA-2, the latter resulted in a higher
KYNA elevation than in the case of KA-1. With regard to TNC, the concentration of KA-
1 was under the limit of detection, while that of KA-2 was quite small and there was no
major difference in the approximately 10-fold KYNA elevations. These findings indicate
that the differences between the beneficial effects of KA-1 and KA-2 may be explained
by the markedly higher peripheral KYNA levels following KA-2 pretreatment. Targeting
the peripheral component of trigeminal pain processing would provide an option for
drug design which might prove beneficial in headache conditions.
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Reviewer #2: The Authors have tried to address the comments of the referees and partially 
improved the manuscript. Some issues still need improvement. 
 
The sentence 'glutamatergic neurotransmission, which plays an essential role in the activation and 
sensitization process during headache disorders' is incorrect. This statement may be true for some 
primary headaches (migraine and chronic migraine), but not for 'headaches' in general. 
The sentence was modified accordingly. 
 
The way the data are presented is still quite confusing: 
Description of the time boundaries for Phase I and II is missing in the Methods section. 
The Methods section was supplemented with the requested information. 
 
A Figure (Fig. 3) has been added in order to attempt to clarify matters, but this figure is extremely 
cryptic and does not serve its purpose. 
In the previous round of reviewing process the referee suggested that a histogram could be 
used to represent the phases of the formalin test. Figure 3 may serve this purpose. The figure 
was restructured and the Results section was supplemented with some information for the 
better understanding. 
 
Table 1 reports the levels of significance for data presented in Figure 2: the table should be 
inglobated in said figure otherwise the reader is forced to go back and forth. 
The requested modification was done in Figure 2 and Table 1 was removed. 
 
Table 2 should be associated to a figure that illustrates mean+sd of time spent in rubbing during the 
2 phases of formalin in the different groups. 
A bar chart (Figure 4) was composed accordingly and Table 2 was removed. The data on the 
authors' response to reviewers' comments Click here to download authors' response to reviewers'
comments rebuttal_letter.doc
effect size, previously presented in Table 2, was implemented in the Results section. 
 
Table 3 should be inglobated in figure 5 for the reason mentioned for Table 1 and Figure 2 (see 
above). 
The requested modification was done in Figure 6 (former Figure 5) and Table 3 was removed. 
 
Concentrations of KYNA and KYNA amides is illustrated in Figure 6 and in Table 4, but the levels 
of statistical significance are missing. 
The aim of measuring the concentrations of KYNA amides and KYNA was to calculate the 
corresponding pharmacokinetic parameters (Table 2) similarly to that in our previously 
published article (Zádori et al., J. Pharm. Biomed. Anal. 55, 540–543). These parameters may 
serve as supplementary information for the better explanation of differences in behavioral 
and immunohistochemical analyses. The current sample size does not allow a comprehensive 
and unbiased comparative statistical analysis, so this kind of assessment was out of the scope 
of the current study. Data presented in Table 1 serve only demonstrative purposes (numerical 
equivalents of that data presented in Figure 7). Of course, if Table 1 is judged to be 
unnecessary by the reviewer or the editor, it can be deleted as well. 
 
The Authors should check the sequence of micrographs in Figure 4: the attenuation of Fos 
expression seems more evident in c (K-1), but the Authors state in the legend that the attenuation 
was more marked following K-2 
Although the amelioration caused by KA-2 is somewhat more pronounced than that of KA-1, 
but this difference is not clearly detectable by the naked eye (< 20%) even if representative 
images are applied. The figure legend was modified accordingly with the elimination of words 
referring to the comparison of the effects of the two KYNA amides based on this 
representative figure. The referee has right that the background staining in Figure 5d (former 
Figure 4d) is slightly higher than that of Figure 5c, but this is not true for the number of black 
spots, i.e. the objects of interest. 
 
Text of the legend to Figure 6 needs corrections: the Authors mention several times fig 4, instead of 
figure 6.  
The legend of Figure 7 (former Figure 6) was corrected. 
 
1 
A comparative assessment of two kynurenic acid analogs in the 
formalin model of trigeminal activation: a behavioral, 
immunohistochemical and pharmacokinetic study 
 
Authors: Gábor Veres1,4,+, Annamária Fejes-Szabó1,+, Dénes Zádori1, Gábor Nagy-Grócz1,5, 
Anna M László3, Attila Bajtai1, István Mándity2, Márton Szentirmai1, Zsuzsanna Bohár1,4, 
Klaudia Laborc1, István Szatmári2, Ferenc Fülöp2, László Vécsei1,4,*, Árpád Párdutz1 
Affiliations: 
1Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, 
University of Szeged, Szeged, Hungary 
2Institute of Pharmaceutical Chemistry, University of Szeged, Szeged, Hungary 
3Department of Biometrics and Agricultural Informatics, Faculty of Horticultural Science, 
Szent Istvan University, Budapest, Hungary 
4MTA-SZTE Neuroscience Research Group, Szeged, Hungary 
5Faculty of Health Sciences and Social Studies, University of Szeged, Szeged, Hungary 
+These authors contributed equally to this work. 
*Corresponding author: 
László Vécsei MD, PhD, DSc 
Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, 
University of Szeged 
Semmelweis u. 6, H-6725 Szeged, Hungary 
Phone: +36 62 545351 
Fax: +36 62 545597 
E-mail: vecsei.laszlo@med.u-szeged.hu 
Manuscript Click here to download Manuscript manuscript.doc 
Click here to view linked References
2 
Abstract 
Kynurenic acid (KYNA) has well-established protective properties against glutamatergic 
neurotransmission, which plays an essential role in the activation and sensitization process 
during some primary headache disorders. The goal of this study was to compare the effects 
of two KYNA analogs, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride (KA-1) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride (KA-2), in the orofacial formalin test of trigeminal pain. Following 
pretreatment with KA-1 or KA-2, rats were injected with subcutaneous formalin solution in 
the right whisker pad. Thereafter, the rubbing activity and c-Fos immunoreactivity changes in 
the spinal trigeminal nucleus pars caudalis (TNC) were investigated. To obtain 
pharmacokinetic data, KA-1, KA-2 and KYNA concentrations were measured following KA-
1 or KA-2 injection. Behavioral tests demonstrated that KA-2 induced larger amelioration of 
formalin-evoked alterations as compared with KA-1 and the assessment of c-Fos 
immunoreactivity in the TNC yielded similar results. Although KA-1 treatment resulted in 
approximately four times larger area under the curve values in the serum relative to KA-2, the 
latter resulted in a higher KYNA elevation than in the case of KA-1. With regard to TNC, the 
concentration of KA-1 was under the limit of detection, while that of KA-2 was quite small 
and there was no major difference in the approximately 10-fold KYNA elevations. These 
findings indicate that the differences between the beneficial effects of KA-1 and KA-2 may be 
explained by the markedly higher peripheral KYNA levels following KA-2 pretreatment. 
Targeting the peripheral component of trigeminal pain processing would provide an option for 
drug design which might prove beneficial in headache conditions. 
 
Keywords: kynurenic acid analog, rat, trigeminal pain, formalin test, pharmacokinetics. 
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1. Introduction 
 
The kynurenine pathway (KP) of the tryptophan (TRP) metabolism is extensively studied, 
mostly because of the well-established endogenous protective properties of kynurenic acid 
(KYNA) against the excitotoxic effect of other KP metabolites, such as quinolinic acid and 3-
hydroxy-L-kynurenine (Vécsei et al., 2013; Zádori et al., 2011b). Thus, KYNA has become a 
molecule of interest for central nervous system (CNS) drug development for several disorders 
(Schwarcz, 2004). The application of KYNA in in vivo preclinical studies would be difficult 
due to its chemical and pharmacokinetic properties. There are problems with its solubility in 
higher doses, it cannot pass the blood-brain barrier in acceptable quantity and it has a rapid 
clearance from the CNS and in the periphery, mediated by organic anion transporters (Bahn et 
al., 2005; Fukui et al., 1991). Several analogs, derivatives and prodrugs have been synthesized 
with the aim of mitigating these disadvantages and of improving the utility of the molecule in 
preclinical studies (Fülöp et al., 2009). Among our newly synthesized KYNA amides, two 
lead compounds have been identified (Patent number #P0900281/ PCT/HU2010/00050). 
With regard to in vitro electrophysiology studies, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride (KA-1, Figure 1a) has been demonstrated to be an 
even more effective inhibitor of hippocampal excitatory synaptic transmission than KYNA 
(Nagy et al., 2011). Accordingly, in an in vivo model of trigeminal activation, KA-1 displayed 
better efficacy than that of its parent compound, KYNA (Knyihar-Csillik et al., 2008). 
Following this comparative study, KA-1 was tested in several experimental setups and proved 
to have beneficial effects (Gellért et al., 2012, 2011; Knyihar-Csillik et al., 2008; Marosi et al., 
2010; Vámos et al., 2010, 2009; Zádori et al., 2011c). In contrast with the electrophysiological 
findings with KA-1, N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride (KA-2, Figure 1b) did not decrease, but rather slightly increased the amplitudes 
of field excitatory postsynaptic potentials (fEPSPs) (Nagy et al., 2011). However, in a recent 
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study, pretreatment with KA-2 was also able to attenuate the effects of nitroglycerine (NTG) 
in an experimental model of migraine (Fejes-Szabó et al., 2014). 
The modes of action of these two compounds are still not fully understood. The two main 
possibilities are the following: 1. The intact structure is necessary for the mechanism of 
action, which would mimic some effects of the parent compound, KYNA. 2. The KYNA 
amides serve as prodrugs and dissociate into KYNA, which can exert its pharmacological 
effects. With regard to the clarification of this issue, only one pharmacokinetic study is 
available to date (Zádori et al., 2011a). In that study, KYNA and KA-1 levels were measured 
with high-performance liquid chromatography (HPLC) in C57B/6 mouse serum following the 
intraperitoneal administration of KA-1. The time-course profile of KA-1 exhibited a steep 
increase in concentration followed by a rapid decrease in the first hour. Although the 
concentration of KYNA also increased from the basal serum level following KA-1 
administration, this increase was considerably less than that in the case of KA-1. It may 
therefore be concluded that only a small proportion of KA-1 is metabolized to KYNA. These 
findings and the results of electrophysiology studies led to the assumption that it is less likely 
that KA-1 acts as a prodrug. Similar pharmacokinetic studies relating to KA-2 have not yet 
been made, but in view of the results of the electrophysiology studies, it seems to have a 
different mode of action. 
The trigeminal system is responsible for most of the pain processing originating from the area 
of the head (Carpenter and Sutin, 1983), and its activation therefore plays an important role in 
the pathomechanism of several neurological disorders, including primary headaches and 
trigeminal pain syndromes. These disorders, including migraine cause an enormous burden to 
the society (Olesen et al., 2012) underlining the need of new treatment options with a possible 
different mechanism of action. On the basis of its antagonistic influence on N-methyl-D-
aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 
kainate receptors (Pereira et al., 2002), it is assumed that KYNA has a modifying effect on 
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nociception (Näsström et al., 1992; Párdutz et al., 2012) and thus might possibly be a future 
candidate in headache treatment. 
One aim of the current study was to investigate the effects of KA-1 and KA-2 in the orofacial 
formalin test in order to quantify the nociception in the trigeminal region of the rat (Clavelou 
et al., 1995; Raboisson and Dallel, 2004). A further aim was to perform a comparative 
pharmacokinetic study so as to further clarify the possible modes of action of these two 
KYNA amides. 
 
2. Materials and methods 
 
2.1 Animals 
 
During the experiments, adult male Sprague-Dawley rats weighing 200-250 g were used. The 
animals were housed under standard laboratory conditions (in an air-conditioned, humidity-
controlled and ventilated room) and were allowed free access to drinking water and regular rat 
chow on a 12 h−12 h dark−light cycle. The procedures used in this study followed the 
guidelines of the International Association for the Study of Pain and the directive of the 
European Economic Community (86/609/ECC). They were approved by the Committee of 
Animal Research at the University of Szeged (I-74-12/2012) and the Scientific Ethics 
Committee for Animal Research of the Protection of Animals Advisory Board 
(XXIV./352/2012.). 
 
2.2 Materials 
 
The new KYNA amides (Patent number #P0900281/PCT/HU2010/00050), KA-1 and KA-2, 
were synthesized in the Department of Pharmaceutical Chemistry, University of Szeged. The 
reference compounds (KYNA and 3-nitro-L-tyrosine (3-NLT)), zinc acetate dihydrate, chloral 
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hydrate and 3,3'-diaminobenzidine were purchased from Sigma-Aldrich (Saint Louis, MO, 
USA), acetonitrile, H2O2, nickel ammonium sulfate and perchloric acid (PCA) were 
purchased from Scharlau (Barcelona, Spain), acetic acid and Triton X-100 were purchased 
from VWR International (Radnar, PA, USA), and paraformaldehyde was purchased from 
Merck (Darmstadt, Germany). The HPLC-MS grade acetonitrile and acetic acid were 
obtained from VWR International (Radnar, PA, USA). 
 
2.3 Behavioral testing 
 
To produce and quantify nociception in the trigeminal region of the rat, we used the orofacial 
formalin test. 
The animals were divided into three groups (n = 27−28 per group) and received an 
intraperitoneal (i.p.) injection of phosphate-buffered saline (PBS, 0.1 M, pH 7.4) in the 
Control group or an i.p. injection of KA-1 (1 mmol/kg body weight; pH 7.4) in the KA-1 
group or an i.p. injection of KA-2 (1 mmol/kg body weight; pH 7.4) in the KA-2 group. One 
hour after pretreatment, the animals were divided further into two subgroups (n = 13−15 per 
subgroup), half of the rats receiving a subcutaneous (s.c.) injection of 50 µl physiological 
saline without formalin (Control, KA-1 and KA-2), while the other half of the rats were 
injected s.c. with 50 µl 1.5% formalin solution containing 0.55% formaldehyde 
(Control−Formalin, KA-1−Formalin and KA-2−Formalin), administered via a 26-gauge 
needle into the right whisker pad. 
The testing procedures were performed during the light phase (between 8 a.m. and 2 p.m.) in a 
quiet room. The test box was a 30 x 30 x 30 cm glass terrarium with mirrored walls. For the 
off-line analysis of rubbing activity directed to the whisker pad, the behavior of the 
individually tested rats was recorded with a video camera (Logitech HD Webcam C615) 
situated 1 m above the terrarium. One hour after pretreatment and following a 10-min 
7 
habituation period in the test box, the whisker pads of the rats were injected s.c. with 
physiological saline or formalin and the animals were immediately replaced in the chamber 
for 45-min. The rats did not receive any food or water during the observation period. The test 
box was cleaned and decontaminated after each animal. An observer blind to the experimental 
procedures analyzed the recorded videos. The 45-min recording period was divided into 15 x 
3-min blocks, and we distinguished two phases following formalin injection ((Phase 1 
(time block 1, i.e., 0-3 min) and Phase 2 (time blocks 5-15, i.e., 12-45 min)) according to 
the previously published methods (Clavelou et al., 1995; Raboisson and Dallel, 2004), and the 
total time (number of seconds) spent in rubbing/scraping the injected area with the ipsilateral 
fore- or hindpaw was measured in each block and defined as the nociceptive score for that 
block. Earlier literature findings led us to use the grooming activity of animals in the Control 
subgroup as control (Clavelou et al., 1995). 
 
2.4 Immunohistochemistry 
 
Four hours after the formalin injection, the rats were perfused transcardially with 100 mL 
PBS, followed by 500 mL 4% paraformaldehyde in phosphate buffer under deep chloral 
hydrate (0.4 g/kg body weight) anesthesia. The medullary segment containing the spinal 
trigeminal nucleus pars caudalis (TNC) between +1 and -5 mm from the obex was removed, 
postfixed overnight for immunohistochemistry in the same fixative and cryoprotected (10% 
sucrose for 2 h, 20% sucrose until the blocks sank, and 30% sucrose overnight). Before 
sectioning, each segment was marked with a small incision on the ventral and left 
(contralateral) side of the tissue block, allowing side discrimination during the quantification 
process. 30-μm transverse cryostat sections were cut through the rostrocaudal axis from the 
beginning of the TNC and were serially collected in wells containing cold PBS. Each well 
contained every tenth section at 0.3-mm intervals along the rostrocaudal axis (15 levels = 
8 
sections). The free-floating sections were rinsed in PBS and immersed in 0.3% H2O2 in PBS 
for 30 min to suppress endogenous peroxidase activity. After several rinses in PBS containing 
1% Triton X-100 (PBST), sections were incubated at room temperature overnight in PBST 
containing rabbit anti-rat c-Fos polyclonal antibody (Santa Cruz Biotechnology, sc-52) at a 
dilution of 1:2000. The immunohistochemical reaction was visualized by using Vectastain 
Elite avidin-biotin kits (Vector Laboratories, PK6101). Briefly, the sections were incubated at 
room temperature for 2 h in PBST containing goat anti-rabbit biotinylated secondary 
antibody. After several rinses in PBST, and incubation at room temperature for 2 h in PBST 
containing avidin and biotinylated horseradish peroxidase, the sections were stained with 3,3’-
diaminobenzidine intensified with nickel ammonium sulfate. The specificity of the immune 
reactions was checked by omitting the primary antiserum. 
The immunoreactive (IR) cells in the superficial layer of the TNC were counted by an 
observer blind to the experimental procedures under the 10x objective of a Nikon Optiphot-2 
(Nikon Instruments, Melville, NY, USA) light microscope in every tenth transverse section in 
each animal. Before the counting, the location of each section along the rostrocaudal axis and 
the location of the TNC on each medullary section were determined by means of The Rat 
Brain in Stereotaxic Coordinates Atlas (Paxinos and Watson, 2007). The c-Fos neurons with 
obvious specific nuclear staining were taken into consideration and were counted in the TNC 
both ipsilaterally and contralaterally to the formalin injection. 
 
2.5 HPLC measurements 
 
2.5.1 Sample preparation 
At set time points (15, 30, 60, 120 and 300 min) following the i.p. injection with the KYNA 
amides (1 mmol/kg), the rats were deeply anesthetized with i.p. injection of chloral hydrate 
(0.4 g/kg, Sigma-Aldrich). Blood samples were collected from vena cava caudalis and 
9 
centrifuged at 13709 RCF (Relative Centrifugal Force) for 10 min at 4°C. The supernatants, 
i.e. the serum samples, were collected and centrifuged at 13709 RCF for 10 min at 4°C again 
and the supernatants were stored at - 80°C until use. After the collection of blood samples, the 
animals were transcardially perfused with 100 ml 0.1 M PBS for 5 min. The CNS samples 
containing the medullary segment of the TNC were then removed and stored at - 80°C until 
measurements. The animals in the Control group underwent a similar procedure with one 
measurement point at 300 min.  
For the measurement of KYNA concentration, the CNS samples were cut in half, weighed and 
then sonicated for 1.5 min in an ice-cooled solution (250 μl) comprising PCA (2.5% w/w), 3-
NLT (10 or 2 µM) and distilled water in an Eppendorf tube. The content of the Eppendorf 
tube was centrifuged at 13709 RCF for 10 min at 4°C and the supernatant was measured. 
Before analysis, the serum samples were thawed and, after a brief vortex, the serum sample 
was 'shot' onto a precipitation solvent (containing PCA with 3-NLT as internal standard, with 
resulting concentrations of 2.5 w/w% and 2 µM, respectively). The samples were 
subsequently centrifuged at 13709 RCF for 10 min at 4°C, and the supernatants were 
collected for measurement. 
For the analysis of KYNA amides, the other half of the CNS samples were weighed and then 
sonicated in ice-cold (250 μl) distilled water for 1.5 min and centrifuged at 13709 RCF for 10 
min at 4°C. From the supernatant, 100 μl was transferred to an Eppendorf tube containing 750 
μl HPLC gradient grade acetonitrile and 150 μl distilled water. After a brief vortex, the 
samples were centrifuged at 13709 RCF for 10 min at 4°C and 900 μl of supernatant was 
evaporated in a vacuum centrifuge. After thawing and brief stirring with a vortex, 200 μl of 
serum sample was transferred to an Eppendorf tube containing 700 μl HPLC gradient grade 
acetonitrile and 100 μl distilled water. After a brief vortex, the samples were centrifuged at 
13709 RCF for 10 min at 4°C and 900 μl of supernatant was evaporated in a vacuum 
centrifuge. The evaporated CNS and serum samples were stored at 4°C until use.  
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2.5.2 Chromatographic conditions 
The KYNA concentrations of the CNS samples were quantified on the basis of a slight 
modification of a literature method (Hervé et al., 1996) as described in detail with method 
validation in our previous article (Fejes-Szabó et al., 2014). For the measurement of 
concentration of the above-mentioned metabolite from serum samples we applied the same 
method with a slight modification. Furthermore, we applied the method validation procedures 
to the serum samples too. Briefly, we used an Agilent 1100 HPLC system (Agilent 
Technologies, Santa Clara, CA, USA) equipped with fluorescence and a UV detector; the 
former was applied for the determination of KYNA and the latter for the determination of the 
internal standard (3-NLT). Chromatographic separations were performed on an Onyx 
Monolithic C18 column, 100 mm x 4.6 mm I.D. (Phenomenex Inc., Torrance, CA, USA) after 
passage through a SecurityGuard pre-column C18, 4 x 3.0 mm I.D., 5 μm particle size 
(Phenomenex Inc., Torrance, CA, USA) with a mobile phase composition of 0.2 M zinc 
acetate/ACN = 95/5 (v/v), the pH of which was adjusted to 6.2 with acetic acid, applying 
isocratic elution. The flow rate was 1.5 ml/min and the injection volume was 20 µl for serum, 
and 50 µl for CNS samples. The fluorescence detector was set at excitation and emission 
wavelengths of 344 and 398 nm. The UV detector was set at a wavelength of 365 nm. 
For the determination of KYNA amides, a Thermo LCQFleet ion trap mass spectrometer was 
used, equipped with an ESI ion source combined with a Dionex Ultimate3000 HPLC system. 
The ionization parameters were as follows: heater temperature: 500°C, sheath gas flow rate: 
60, auxiliary gas flow rate: 20, spray voltage: 4 kV, capillary temperature: 400°C. 
Chromatographic separations were performed on a Kinetex C18 column, 100 mm × 4.6 mm, 
2.6 μm particle size (Phenomenex Inc., Torrance, CA, USA ) after passage through a 
SecurityGuard pre-column C18, 4 x 3.0 mm, 5 μm particle size (Phenomenex Inc., Torrance, 
CA, USA), with a mobile phase composition of 0.05% aqueous CH3COOH/ACN = 90/10 
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(v/v), applying isocratic elution. The flow rate and the injection volume were 1 ml/min and 50 
μl, respectively. 
 
2.5.3. Calibration curve and linearity 
Calibrants were prepared at 6 different concentration levels, from 1 to 100 nM, 0.5 to 5 µM 
and 0.01 to 100 µM for KYNA, 3-NLT and the KYNA amides, respectively. Three parallel 
injections of each solution were made under the chromatographic conditions described above. 
The peak area responses were plotted against the corresponding concentration, and the linear 
regression computations were carried out by the least square method with the freely available 
R software (R Development Core Team, 2002). Very good linearity was observed throughout 
the investigated concentration ranges for KYNA, 3-NLT and the KYNA amides when either 
fluorescence, UV or MS detection was applied. 
 
2.5.4 Selectivity 
The selectivity of the method was checked by comparing the chromatograms of KYNA, 
KYNA amides and the internal standard for a blank serum and CNS sample and those for a 
spiked sample. All compounds could be detected in their own selected chromatograms 
without any significant interference. 
 
2.5.5 LOD and LLOQ 
The limit of detection (LOD) and the lower limit of quantification (LLOQ) were determined 
via the signal-to-noise ratio with a threshold of 3 and 10, respectively, according to the ICH 
guidelines (ICH, 1995). The LOD and LLOQ for KYNA in the serum samples were 1 nM and 
3.75 nM, respectively, while in the CNS samples they were 0.4 nM and 1 nM, respectively. 
The LOD and LLOQ for the samples in MS detection were 0.001 μM and 0.015 μM, 
respectively. 
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2.5.6 Precision 
Replicate HPLC analysis showed that the relative standard deviation was ≤ 2.2% for the peak 
area response and ≤ 0.1% for the retention time for KYNA and the KYNA amides. 
 
2.5.7 Recovery 
The relative recoveries were estimated by measuring spiked samples of KYNA and the 
KYNA amides at 2 concentrations with 3 replicates of each. No significant differences were 
observed for the lower and higher concentrations. The recoveries for the serum samples 
ranged from 103 to 108%, 81 to 94% and 79 to 80% for KYNA, KA-1 and KA-2, 
respectively. The recoveries for the CNS samples ranged from 82 to 92% and 78 to 84% for 
KYNA and KA-2, respectively. 
 
2.6 Data evaluation 
 
To compare the means of jaw rubbing counts (orofacial formalin tests) in the different 
treatment groups (Control, Control−Formalin, KA-1, KA-1−Formalin, KA-2, KA-
2−Formalin) on rats during 15 3-min time periods (n = 13−15 animals in each group), two-
way repeated measures ANOVA were run. Treatment with 6 groups was used as between-
subject factor and time with 15 time points as within-subject factor for the analysis. 
When Levene's test for homogeneity of variance was significant in the Phase data (Phase 1 is 
the first 3 min, while Phase 2 is the overall rubbing from min 12 to the end of the 
examination, min 45, i.e. which is from the 5th 3-min time period to the 15th), the Welch test 
was run to compare mean rubbing counts. Pairwise comparisons were estimated by the Sidak 
test. The effect size (EF, f) was calculated according to Cohen J. (Cohen, 1988) with regard to 
the ANOVA tests comparing the effects of compounds on behavioral data in Phase 1 and 2. 
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In the case of the immunohistochemistry data, the numbers of c-Fos-containing nuclei were 
assessed. Three-way repeated measures ANOVA was used to analyze group means across 15 
adjacent measuring sites (consequent slices from the medullary segment of the CNS 
containing the TNC) among sides (contralateral and ipsilateral) and between pretreatment 
groups (Control, KA-1 and KA-2) all with formalin injections. Measuring sites and sides were 
used as within-subject factor, while pretreatment was the between-subject factor in the 
General Linear Model. 
In the ANOVA models when Mauchly’s test of sphericity was significant, the Greenhouse-
Geisser correction was performed. In the event of the significant interaction of factors, effects 
could not be reported independently. Moreover owing to the significant interaction, group 
differences could be examined separately over the within-subject factor based on estimated 
marginal means for multiple comparisons with the Sidak adjustment. 
Statistical analyses were carried out with IBM SPSS Statistics, version 21 (IBM Corporation, 
Armonk, NY, USA) software. All tests were two-sided, and p < 0.05 was considered to be 
statistically significant. The pharmacokinetic data were evaluated with PKSolver, a freely 
available menu-driven add-in program for Microsoft Excel (Zhang et al., 2010). 
 
3. Results 
 
3.1 Behavioral assessment 
 
The results of orofacial formalin testing are demonstrated in Figure 2, 3 and 4. To simplify 
the presentation of group comparisions for better tranparency the groups of KA-1 and 
KA-2 were omitted from Figures 2, 3 and 4. Pairwise comparisons revealed that face 
rubbing activity in the Control, KA-1 and in the KA-2-treated groups was significantly lower 
as compared with the Control−Formalin (ES of Phase 1: -1.88 and Phase 2: -2.17), KA-
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1−Formalin (ES of Phase 1: -1.75 and Phase 2: -1.56) and KA-2−Formalin (ES of Phase 1: 
-1.64 and Phase 2: -1.26) groups, in both Phase 1 and Phase 2. With regard to the comparison 
of the face rubbing activity in the KA-1−Formalin (ES of Phase 1: 0.11 and Phase 2: 0.51) 
and KA-2−Formalin (ES of Phase 1: 0.16 and Phase 2: 0.76) groups with that in the 
Control−Formalin group, although KA-1 decresead face rubbing activity as well 
(demonstrated by the corresponding left-skewed histogram in Figure 3), only KA-2 
treatment resulted in a significant reduction in the middle of Phase 2 (Figures 2 and 4). 
 
3.2 Immunohistochemistry 
 
The results of immunohistochemical analysis are demonstrated in Figures 5 and 6. The 
comparison of the ipsilateral and the contralateral sides of the slices from the medullary 
segment of the rat CNS containing the TNC demonstrated that the mean number of c-Fos IR 
neurons was significantly higher on the ipsilateral side than on the contralateral side in the 
Control−Formalin, KA-1−Formalin and KA-2−Formalin groups (the two latter groups are 
not demonstrated to simplify the presentation of group comparisions for better 
tranparency  in Figure 6). With regard to the comparison of the ipsilateral sides of the KA-
1−Formalin and KA-2−Formalin groups with the Control−Formalin group from the aspect of 
the mean number of c-Fos IR neurons, the treatments, preferentially with KA-2, resulted in 
significant reductions in IR cell count at certain levels of the assessed region (the c-Fos 
changes followed the somatotopic representation of the trigeminal nociceptors in the injected 
whisker pad area (Strassman and Vos, 1993)). Besides the observed significant differences, 
the effects of the treatment are well demonstrated by the curves in Figure 6. 
 
3.3 HPLC measurements and pharmacokinetics 
 
15 
The concentrations of KYNA and KYNA amides measured in rat serum and CNS samples by 
HPLC are demonstrated in Table 1. The time-course profile of the KYNA amides in the rat 
serum revealed that, after a steep increase in the concentration, a subsequent steep decrease 
occurred in the first hour, followed by a prolonged further gradual decrease (Figure 7). 
Although the serum concentration of KA-2 did not show such a high level as that of KA-1, a 
slightly slower decrease in concentration was observed. These observations are consistent 
with the calculated serum pharmacokinetic parameters (Cmax, Tmax, area under the curve 
(AUC0-t), the half-life (t1/2), apparent total clearance (CL/Fobs) and apparent volume of 
distribution (Vz/Fobs)) of KA-1 and KA-2, demonstrated in Table 2. However, the increase in 
serum KYNA concentration following the i.p. injection of KA-2 was considerably higher (an 
approximately 200-fold maximal increase) as compared with that of KA-1 (an approximately 
70-fold maximal increase), also well reflected by the above-mentioned pharmacokinetic 
parameters. To avoid the influence of the basal serum KYNA level on the calculated 
pharmacokinetic parameters, these basal concentrations were subtracted from the 
corresponding subsequent concentrations in the calculation of the pharmacokinetic 
parameters. The pharmacokinetic data therefore reflect only the KYNA amide-induced 
changes in KYNA concentrations. In the fifth hour, KA-1 and KA-2 were still present at 3.1 
(0−61.5) µM and 0.5 (0.5−0.5) µM in the serum, respectively, while the KYNA levels had 
approximately returned to the baseline level, preferentially in the case of KA-1 treatment. In 
the rat CNS samples the KA-1 concentration was under LOD. However, KA-2 was present in 
detectable amounts in the CNS, reaching its maximum concentration (6.44 (5.62−7.85) 
pmol/g ww) after an hour which subsequently gradually decreased but in the fifth hour it was 
still present at 1.98 (1.50−2.90) pmol/g ww. The CNS pharmacokinetics of KYNA following 
KA-1 and KA-2 administration showed quite similar profiles, characterized by an 
approximately maximal 10-fold increase in basal concentration within the first hour. Vz/Fobs 
was relatively high in KA-1 and especially in KA-2. The apparent clearance was also high in 
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the case of KA-2 relative to KA-1. 
 
4. Discussion 
 
Headache, one of the most common disorders of the nervous system, is a major health 
problem worldwide. The global prevalence for the adult population of active headache 
disorder is 46% for headache in general, 11% for migraine, 42% for tension-type headache 
and 3% for chronic daily headache (Stovner et al., 2007). The treatment of primary headache 
disorders is challenging requiring both acute and preventive therapeutic strategies 
(Weatherall, 2015). The efficacy of these treatments is not always satisfactory and the 
contraindications and side-effects often limit the options of the physician (Diener et al., 2015; 
Obermann et al., 2015). There is therefore a constant need to study and develop new 
molecules. In addition to the currently available drugs, such as NSAIDs, triptans, 
anticonvulsants, verapamil, propanolol, etc. (National Institute for Health and Care 
Excellence, 2012), the pipeline of pharmaceutical research in this field involves the 
development of novel agents acting on the glutamatergic system due to its essential role in the 
nociceptive process (Dickenson et al., 1997; Diener et al., 2015). Animal and human studies 
have revealed that glutamate receptors are present in various parts of the trigeminal system 
(Quartu et al., 2002; Sahara et al., 1997; Tallaksen-Greene et al., 1992), and stimulation of the 
trigeminal nerve results in elevated glutamate levels in the TNC (Oshinsky and Luo, 2006). 
The peripheral application of glutamate to deep craniofacial tissue proved to be able to 
activate and sensitize nociceptive afferents and neurons in the upper cervical cord (Lam et al., 
2009a; Lam et al., 2009b). These findings suggest that excitatory amino acid receptors (and 
NMDA in particular) play an important role in pain processing and the sensitization process 
which is also present in migraineurs (Vikelis and Mitsikostas, 2007). Ketamine, an NMDA 
antagonist, is so far the only promising treatment option for patients with severe or long-
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lasting migraine aura (Afridi et al., 2013). Another novel substance, tezampanel, which acts 
on the AMPA and kainate subtypes of ionotropic glutamate receptors (Alt et al., 2006), has 
also shown promising results in acute migraine therapy (Sang et al., 2004). 
As regards the preclinical models of headache disorders, NTG is the most frequently used 
substance to trigger a delayed migraine-like attack (Sicuteri et al., 1987). Animal experiments 
have revealed that NTG can activate the trigeminal system and stimulate the second-order 
trigeminal neurons, which leads to increased c-Fos and neuronal nitric oxide synthase (nNOS) 
expression in the affected area (Pardutz et al., 2000; Tassorelli et al., 1997). NTG is also able 
to sensitize the trigeminal system in humans (Di Clemente et al., 2009). Together, these results 
confirm that NTG administration can model the central trigeminal nociceptor sensitization 
demonstrated in migraine patients (Burstein et al., 2000). With regard to the above-mentioned 
therapeutic strategy with the aim of neurotransmission modulation via the glutamatergic 
system, earlier studies revealed that KA-1 is able to attenuate the effects of NTG on the 
number of nNOS, calcium/calmodulin-dependent protein kinase II type alpha (CamKIIα) and 
calcitonin gene related peptide (CGRP) IR cells in the TNC, markers related to the activation 
and sensitization of the nociceptors (Vámos et al., 2010, 2009). KA-2 was later also tested in 
the NTG model and proved to be able to increase the KYNA concentration both in the C1−C2 
region and in the serum. Pretreatment with KA-2 (0.5 and 1 mmol/kg) significantly reduced 
the effects of NTG on the CGRP-, c-Fos-, nNOS- and CaMKIIα-related changes in the C1–C2 
region (Fejes-Szabó et al., 2014). To date there has been only one study of the 
pharmacokinetic properties of KYNA amides, which found that only a small proportion of 
KA-1 decays into KYNA in the serum of C57B/6 mice (Zádori et al., 2011a). 
In the present study, we used another well-known model of trigeminal nociception, the 
orofacial formalin test. Formalin solution administered s.c. into the upper lip of rats causes 
tissue injury, inflammation and nociception (Clavelou et al., 1995). Immunohistochemical 
studies have revealed that formalin induces c-Fos and nNOS expression in the TNC, similarly 
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as in the NTG model, which suggests the activation and sensitization of the area (Hunt et al., 
1987; Pardutz et al., 2000). The behavioral effect of formalin is biphasic, with a short period 
of rubbing activity immediately after injection and then a tonic prolonged (20-22 min) second 
phase after a quiescent period (Raboisson and Dallel, 2004). By using the formalin model, our 
aim was to compare the two compounds (KA-1 and KA-2) in an assessment method which 
involves both peripheral and central components of pain processing, with special interest in 
the pharmacokinetic explanation of the observed differences. 
Our results indicated that KA-2 has more significant beneficial effects on the formalin-
induced behavioral and immunohistochemical alterations. We carried out a comparative 
pharmacokinetic study to clarify this difference between the two analogs. With regard to the 
serum concentrations of the analogs following their i.p. administration, the levels of KA-2 
were considerably lower than those of KA-1 from the aspects of peak concentration and 
AUC0-5h. In contrast, KA-1 could not be detected in the examined CNS region, and the 
concentration of KA-2 was likewise relatively low. On the other hand, the serum 
pharmacokinetic data revealed that KA-2 decays into KYNA in larger amount as compared 
with KA-1, but nevertheless, in the examined CNS region, there is no major difference 
between KYNA levels following the treatments with KA-1 or KA-2. Summarizing these 
findings, the peak elevation of KYNA in the CNS (approximately tenfold of the basal 
concentration) is considerably lower (by one order of magnitude) than that of peak elevation 
of KYNA in the serum (approximately 70-200-fold of the basal concentration) following the 
administration of KA-1 and KA-2, and with respect to CNS samples, there are no differences 
between KYNA levels. In view of these findings, the difference in the observed effects in 
behavioral and immunohistochemical studies could be explained by the differences in serum 
KYNA levels. From the aspect of a structure−activity relationship, the difference in peripheral 
conversion may stem from the structures of the two analogs, e.g. in the case of KA-2 the 
strained pyrrolidine moiety may influence the faster hydrolysis of the amide bond relative to 
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the N,N-dimethyl function (KA-1). These findings suggest that the difference in the beneficial 
effects of the two analogs may be explained by the peripheral effect of elevated KYNA 
concentrations on formalin-induced pathological alterations. The molecular background 
would be the inhibition of NMDA receptor-mediated neurotransmission at the strychnine-
insensitive glycine-binding site (Szalárdy et al., 2012) which is present on the peripheral 
process of the trigeminal nociceptors (Quartu et al., 2002; Watanabe et al., 1994). The 
observed peak serum KYNA concentration following KA-2 treatment during the experiment 
(16.71 µM) would be relevant with regard to the inhibition of glutamatergic 
neurotransmission via the above-mentioned possibility (Szalárdy et al., 2012). 
In conclusion, our results draw attention to the role of influencing the glutamatergic system in 
the alleviation of peripheral sensitization, which can be utilized during future drug 
development. The possibility of targeting the peripheral component of pain processing would 
provide an option of pharmaceutical drug design without the obligation of good penetration 
through the BBB, but other pharmacokinetic parameters, such as solubility and clearance, 
must be kept in mind. The present results and previous preclinical findings indicate that the 
KYNA amides, via their probable direct effects (KA-1; Zádori et al., 2011a) or serving as 
prodrugs (KA-2 in the current phamacokinetic study), would be promising drug candidates in 
neurological disorders, including those involving pain and headache, with a high 
socioeconomic burden. 
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8. Figure captions 
 
Fig. 1 The chemical structure of N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride (KA-1, a) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride (KA-2, b) 
 
Fig. 2 The effects of formalin and KYNA amide treatments on Sprague-Dawley male rats in 
the orofacial formalin tests. Following formalin injection, the recording period was 45-min 
and this time period was divided into 15 x 3-min time blocks. Phase 1 (time block 1) of the 
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test is before the grayed out area, while Phase 2 (time blocks 5-15) is after the grayed out area. 
The two phases of formalin action in the Control + Formalin group are well 
demonstrated when compared to the Control group (* p < 0.05; ** p < 0.01; *** p < 
0.001). The KA-2 pre-treatment significantly reduced the formalin-induced nociceptive 
behavior relative to the Control + Formalin group (++ p < 0.01; +++p < 0.001). Sprague-
Dawley male rats: n = 13−15 in each group; data are shown as means ± SEM; KA-1 N-(2-
N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride; KA-2 N-(2-N-
pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride 
Fig. 3 Distribution of rubbing activity by groups in Phase 1 and 2 of the orofacial formalin 
test. The recording period was 45-min, Phase 1 is the first 3-min, while Phase 2 is the overall 
rubbing activity from min 12 to the end of the examination. Sprague-Dawley male rats: n = 
13−15 in each group; KA-1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride; KA-2 N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride 
 
Fig. 4 Diagrams showing the rubbing activity in the first (a) and the second (b) phase in 
the orofacial formalin test. In the Control + Formalin group, the subcutaneous formalin 
injection induced a significant increase in rubbing activity in both Phase 1 and 2 (*** p < 
0.001) as compared to the Control group. In Phase 2, pre-treatment with KA-2 had a 
significant effect on mitigating the formalin-induced increase in the time spent with 
rubbing (++ p < 0.01) as compared with the Control + Formalin group. Sprague-Dawley 
male rats: n = 13−15 in each group; Data are presented as mean ± S.E.M.;   KA-1 N-(2-
N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride; KA-2 N-(2-
N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride 
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Fig. 5 Representative histological images following c-Fos immunostaining in Sprague-
Dawley male rats. Subcutaneous formalin injection induced an increase in the number of c-
Fos IR neurons on the ipsilateral side demonstrated on the transverse section of medulla 
containing the TNC from the Control-Formalin subgroup (a-b; contralateral side is indicated 
with an incision on the ventral side of the section). The pretreatments (KA-1: c; KA-2: d), 
reduced the amount of IR cells in the superficial layers of TNC as compared with Control + 
Formalin group (b). black arrow: c-Fos IR neurons in the superficial laminae; black frame: 
magnified area, which can be seen in images b-d; TNC trigeminal nucleus pars caudalis; IR 
immunoreactive; KA-1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride; KA-2 N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride 
 
Fig. 6 The average number of c-Fos immunoreactive cells per section of TNC in Sprague-
Dawley male rats after formalin injection with KYNA amide pretreatments. The distance was 
calculated caudally from the starting point of TNC. Subcutaneous formalin injection 
resulted in a higher number of c-Fos-IR neurones on the ipsilateral side compared with 
the contralateral side in the Control + Formalin group (* p < 0.05; ** p < 0.01; *** p < 
0.001). The pretreatments (KA-1: # p < 0.05, ## p < 0.01; KA-2: ++ p < 0.01), reduced the 
amount of IR cells in the superficial layers of TNC as compared with the ipsilateral side 
in the Control + Formalin group. Sprague-Dawley male rats: n = 9–10 in each group; data 
are shown as means ± SEM; IR immunoreactive; TNC trigeminal nucleus pars caudalis; KA-
1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride; KA-2 
N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride 
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Fig. 7 The concentrations of KYNA and KYNA amides in serum and CNS samples of 
Sprague-Dawley male rats. Figure 7a and 7b indicate the concentrations of KYNA and KYNA 
amides in rat serum with the course of time after injection. Figure 7c and 7d shows the 
concentrations of KYNA and KYNA amides in the CNS samples of the same animals. KA-1 
concentrations were under the limit of detection in the CNS samples. Sprague-Dawley male 
rats: n = 5 in each group; data are shown as medians; KYNA kynurenic acid, KA-1 N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, KA-2 N-(2-N-
pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride 
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Figure 7
 Serum CNS 
 KA-1 treatment KA-2 treatment KA-1 treatment KA-2 treatment 
Time 
(min) 
KA-1 (µM) KYNA (nM) KA-2 (µM) KYNA (nM) 
KA-1 
(pmol/g ww) 
KYNA 
(pmol/g ww) 
KA-2 
(pmol/g ww) 
KYNA 
(pmol/g ww) 
0 
(control) 
0 
75.7 
(72.8−90.4) 
0 
75.7 
(72.8−90.4) 
0 
5.33 
(1.00−13.17) 
0 
5.33 
(1.00 - 13.17) 
15 
87.4 
(0−191.2) 
5517.9 
(3287.2−6290.1) 
2.6 
(2.2−20.9) 
287.9 
(239.1−6753.5) 
< LOD 
58.98 
(53.37−277.22) 
< LOD 
17.41 
(15.02−19.31) 
30 
35.6 
(0−140.4) 
1159.3 
(523.8−2397.9) 
20.9 
(17.4−22.6) 
16709.5 
(13796.6−17519) 
< LOD 
44.69 
(29.43−104.13) 
4.45 
(3.88−4.67) 
34.77 
(25.01−50.53) 
60 
39.6 
(0−114.4) 
464.1 
(304.9−1342.3) 
13.7 
(13.7−14) 
3375.8 
(3332.7−4604.1) 
< LOD 
58.61 
(25.97−103.53) 
6.44 
(5.62−7.85) 
65.70 
(41.54−110.68) 
120 
19.5 
(0−87.2) 
561 
(353.2−570.4) 
3.2 
(3−4.7) 
334.6 
(232.4−422.2) 
< LOD 
12.00 
(11.07−15.68) 
3.28 
(2.75−3.31) 
15.30 
(10.81−18.47) 
300 
3.1 
(0−61.5) 
103.6 
(99.1−128.2) 
0.5 
(0.5−0.5) 
149.3 
(110.3−150.1) 
< LOD 
13.73 
(13.16−19.79) 
1.98 
(1.50−2.90) 
22.43 
(19.63−24.62) 
 
Table 1 The concentration of KYNA and KYNA amides in Sprague-Dawley male rat serum and CNS samples. The concentrations were 
measured with HPLC after pretreatment with KA-1 and KA-2. Sprague-Dawley male rats: n = 5 in each group; data are shown as median 
(interquartile range); KYNA kynurenic acid, KA-1 N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, KA-2 N-(2-
N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, LOD limit of detection. 
 
Table 1
 Serum CNS 
 KA-1 treatment KA-2 treatment  KA-1 treatment KA-2 treatment 
Pharmacokinetic 
parameters 
KA-1 KYNA KA-2 KYNA 
Pharmacokinetic 
parameters 
KA-1 KYNA KA-2 KYNA 
t1/2 (h) 1.09 0.91 0.84 0.64 t1/2 (h) NA 1.67 2.61 3.45 
tmax (h) 0.25 0.25 0.50 0.50 tmax (h) NA 0.25 1 1 
Cmax (µM) 87.44 5.44 20.87 16.63 Cmax (pmol/g) NA 53.66 6.44 60.37 
AUC 0 - t (µM*h) 99.22 2.61 23.35 7.89 AUC 0 - t (pmol/g*h) NA 86.46 16.24 97.77 
Vz/Fobs 
((μmol/kg)/(μmol/l)) 
15.17 - 50.02 - 
Vz/Fobs 
((pmol/kg)/(pmol/l)) 
NA - 158879.15 - 
Cl/Fobs 
((μmol/kg)/(μmol/l)/h) 
9.61 - 41.81 - 
Cl/Fobs 
((pmol/kg)/(pmol/l)/h) 
NA - 42220.03 - 
 
Table 2 Pharmacokinetic parameters of KYNA and KYNA amides in rat serum and CNS samples after intraperitoneal injection of KA-1 and 
KA-2. The KYNA amides were applied in a dose of 1 mmol/kg. Sprague-Dawley male rats: n = 5 in each group; KYNA kynurenic acid, KA-1 N-
(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, KA-2 N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride 
 
Table 2
